monoclonal antibody hu3S193

BIOLOGICAL4 trials

Sponsors

Ludwig Institute for Cancer Research, Recepta Biopharma

Conditions

Colorectal CancerFallopian Tube CancerLung CancerOvarian CancerPeritoneal Cavity Cancer

Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

TerminatedNCT00006046

Ludwig Institute for Cancer ResearchColorectal Cancer

Start: 2000-07-12End: 2002-09-24Updated: 2023-10-04

Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer

TerminatedNCT00006099

Ludwig Institute for Cancer ResearchOvarian Cancer

Start: 2000-08-02End: 2002-08-12Updated: 2023-10-04

Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)

CompletedNCT00084799

Ludwig Institute for Cancer ResearchLung Cancer

Start: 2004-07-26End: 2006-12-20Updated: 2023-10-04

Phase 2

Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

TerminatedNCT01137071

Recepta BiopharmaFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer

Start: 2011-04-30End: 2015-06-30Updated: 2017-02-23

Related Papers

Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.

2021-03-045 citations

Anti-LeY monoclonal antibody (mAb) hu3S193 as consolidation therapy for patients (pts) with relapsing platinum sensitive ovarian cancer (OC) after achieving a second complete response (2CR).

Journal of Clinical Oncology2017-05-20